PBAC's latest decision on Inactivated quadrivalent influenza vaccine (split virion): Recommended with restriction (2020). Considered for Extension of existing listing to include vaccination of healthy children aged 6 months to <5 years for the prevention of seasonal influenza, to align with current NIP listings for other QIVs in this population.
PBAC outcome
Recommended with restriction
Restricted
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
3
first 2018
Submissions
3
2018 → 2020
Eligible population
Healthy children aged 6 months to <5 years eligible for free vaccination under the National Immunisation Program.
Therapy area
Vaccines
Line of therapy
Not applicable
Evidence base
RCT
Primary endpoint
ORR
Pivotal trial size
6,006 patients
Key trials
D-QIV-004, GQM05, D-QIV-009, D-QIV-015, Q-QIV-022
Comparator
Vaxigrip Tetra (primary); FluQuadri (alternative)
Economic model
Cost-minimisation
ICER note
Minor submission with cost-minimisation basis; no ICER calculated as this was a vaccine listing extension rather than a new drug economic evaluation.
Submission history
Nov 2018: Recommended with restriction · Restricted
Nov 2019: Recommended with restriction · Restricted
Jul 2020: Recommended with restriction · Restricted